Home LiteratureArticle Details
PMID: 28198439 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

MIAT Is a Pro-fibrotic Long Non-coding RNA Governing Cardiac Fibrosis in Post-infarct Myocardium.

Scientific reports ·Vol. 7 ·2017-00-15 ·Pages 42657

Qu X, Du Y, Shu Y, Gao M, Sun F, Luo S, Yang T, Zhan L, Yuan Y, Chu W, Pan Z, Wang Z, Yang B, Lu Y

Abstract

A long non-coding RNA (lncRNA), named myocardial infarction associated transcript (MIAT), has been documented to confer risk of myocardial infarction (MI). The aim of this study is to elucidate the pathophysiological role of MIAT in regulation of cardiac fibrosis. In a mouse model of MI, we found that MIAT was remarkably up-regulated, which was accompanied by cardiac interstitial fibrosis. MIAT up-regulation in MI was accompanied by deregulation of some fibrosis-related regulators: down-regulation of miR-24 and up-regulation of Furin and TGF-β1. Most notably, knockdown of endogenous MIAT by its siRNA reduced cardiac fibrosis and improved cardiac function and restored the deregulated expression of the fibrosis-related regulators. In cardiac fibroblasts treated with serum or angiotensin II, similar up-regulation of MIAT and down-regulation of miR-24 were consistently observed. These changes promoted fibroblasts proliferation and collagen accumulation, whereas knockdown of MIAT by siRNA or overexpression of miR-24 with its mimic abrogated the fibrogenesis. Our study therefore has identified MIAT as the first pro-fibrotic lncRNA in heart and unraveled the role of MIAT in the pathogenesis of MI. These findings also promise that normalization of MIAT level may prove to be a therapeutic option for the treatment of MI-induced cardiac fibrosis and the associated cardiac dysfunction.

MeSH Terms
Animals Cell Proliferation Cell Survival Collagen/metabolism Disease Models, Animal Echocardiography Fibroblasts/metabolism Fibrosis Gene Expression Regulation Gene Knockdown Techniques Heart Function Tests Male Mice MicroRNAs Myocardial Infarction/diagnosis,genetics,pathology,physiopathology Myocardium/metabolism,pathology RNA, Long Noncoding/genetics RNA, Small Interfering/genetics
Chemicals
Miat long non-coding RNA MicroRNAs Mirn24 microRNA, mouse RNA, Long Noncoding RNA, Small Interfering Collagen
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Qu Xuefeng
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China. | Northern Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, Heilongjiang 150081, P. R. China.
Du Yue
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Shu You
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Gao Ming
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Sun Fei
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Luo Shenjian
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Yang Ti
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Zhan Linfeng
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Yuan Yin
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Chu Wenfeng
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Pan Zhenwei
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Wang Zhiguo
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Yang Baofeng
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China.
Lu Yanjie
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, P.R China. | Northern Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, Heilongjiang 150081, P. R. China.
References (30)
30 references, click to expand
  1. X-inactivation, imprinting, and long noncoding RNAs in health and disease.
    Cell. 2013 Mar 14;152(6):1308-23 PMID: 23498939
  2. APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p.
    Nat Commun. 2015 Apr 10;6:6779 PMID: 25858075
  3. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway.
    Circulation. 2012 Aug 14;126(7):840-50 PMID: 22811578
  4. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction.
    J Hum Genet. 2006;51(12):1087-99 PMID: 17066261
  5. Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase.
    Cardiovasc Res. 2004 Jul 1;63(1):87-97 PMID: 15194465
  6. [Long non-coding RNAs with enhancer-like function in human cells].
    Med Sci (Paris). 2011 Apr;27(4):359-61 PMID: 21524398
  7. Identification of a shared genetic susceptibility locus for coronary heart disease and periodontitis.
    PLoS Genet. 2009 Feb;5(2):e1000378 PMID: 19214202
  8. How cells read TGF-beta signals.
    Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78 PMID: 11252892
  9. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489.
    Circ Res. 2014 Apr 25;114(9):1377-88 PMID: 24557880
  10. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals.
    Nature. 2009 Mar 12;458(7235):223-7 PMID: 19182780
  11. A long noncoding RNA protects the heart from pathological hypertrophy.
    Nature. 2014 Oct 2;514(7520):102-6 PMID: 25119045
  12. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes.
    J Cell Mol Med. 2014 Mar;18(3):415-21 PMID: 24428157
  13. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling.
    Circ Res. 2009 Jan 30;104(2):170-8, 6p following 178 PMID: 19096030
  14. No-nonsense functions for long noncoding RNAs.
    Cell. 2011 Apr 15;145(2):178-81 PMID: 21496640
  15. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts.
    Circ Res. 2010 Jan 8;106(1):166-75 PMID: 19893015
  16. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue.
    Cardiovasc Res. 2009 Apr 1;82(1):21-9 PMID: 19147652
  17. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation.
    Nat Commun. 2014 Apr 07;5:3596 PMID: 24710105
  18. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction.
    J Cell Mol Med. 2012 Sep;16(9):2150-60 PMID: 22260784
  19. Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome.
    Cardiovasc Res. 2012 Oct 1;96(1):90-8 PMID: 22853924
  20. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.
    Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13027-32 PMID: 18723672
  21. Regulatory variation in a TBX5 enhancer leads to isolated congenital heart disease.
    Hum Mol Genet. 2012 Jul 15;21(14):3255-63 PMID: 22543974
  22. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA.
    Cell. 2011 Oct 14;147(2):358-69 PMID: 22000014
  23. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
    Circulation. 2007 Feb 6;115(5):e69-171 PMID: 17194875
  24. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling.
    Cardiovasc Res. 2007 May 1;74(2):184-95 PMID: 17109837
  25. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus.
    Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1671-7 PMID: 19592466
  26. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy.
    Circ Res. 2002 Dec 13;91(12):1103-13 PMID: 12480810
  27. Connective tissue growth factor and cardiac fibrosis after myocardial infarction.
    J Histochem Cytochem. 2005 Oct;53(10):1245-56 PMID: 15956033
  28. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA.
    Circ Res. 2015 Mar 27;116(7):1143-56 PMID: 25587098
  29. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study.
    Circulation. 2007 Mar 27;115(12):1544-50 PMID: 17353438
  30. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.
    J Am Coll Cardiol. 2001 Oct;38(4):1207-15 PMID: 11583905
Article Info
Journal
Scientific reports
Abbr.
Sci Rep
ISSN
2045-2322
Published
2017-00-15
Epub
2017-00-15
Pages
42657
Language
English
Region
England
NLM ID
101563288
PMCID
PMC5309829
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com